Boston Scientific Bets Big On Monitoring; Buys Preventice For Up To $1.25Bn

The deal is the fourth major acquisition in the remote monitoring market in the last five weeks after Philips acquired BioTelemetry and Capsule and Hillrom bought Bardy Diagnostics.

Abstract medical cardiology ekg background
• Source: shutterstock.com

Boston Scientific is the latest company to make a big investment in the fast-growing remote diagnostics and services market with an agreement to buy ambulatory cardiac monitoring company Preventice Solutions for $925m in cash and up to $300m in potential milestones.

"This acquisition will provide Boston Scientific with a foothold in the high-growth ambulatory electrocardiography space,” Scott Olson, president of Boston Scientific’s rhythm management business said. “[Preventice] will serve as an...

More from Deals

More from Business

Medtronic Eyes Up to $350M Tariff Hit in FY26, Leans On Cost Controls And Pricing Strategy

 
• By 

Medtronic expects operating profit to grow approximately 7% in fiscal 2026, excluding tariff impacts. If tariffs materialize at the upper end of the projected range, operating profit growth could drop by 2.2 to 3.2 percentage points.

India-UK Free Trade Agreement Sets Stage For Medtech Growth, But Industry Demands Safeguards

 
• By 

Announced after three years of negotiation, the FTA eliminates tariffs on 99% of Indian product types, covering nearly all trade value, and reduces tariffs on 90% of UK products. Although not yet formally signed, the deal is being positioned by the Indian government as “transformative,” with an estimated economic impact of $6.4bn for the UK alone by 2040.

Medtronic To Spin Out Diabetes Unit As New Products Solidify Turn-Around Story

 
• By 

Medtronic’s diabetes spin-out – a process likely to run up to 18 months and involve 20% IPO followed by a split-off for Medtronic shareholders – will allow firm to focus on higher-margin devices.